Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Misr International University | OTHER |
Not provided
Not provided
Not provided
Not provided
The COVID-19 infection severity depends on many factors, including genetic factors. The SNPs of ACE1, ACE2 and TMPRSS2; which have a big role in the viral entry to the cells, will be tested and help establish a relationship between the genetic variation in these SNPs and the severity of the COVID-19 symptoms. The aim of this study is to detect the association between ACE1, ACE2 and TMPRSS2 gene polymorphism variants and occurrences of severe complications in Egyptians patients with COVID-19 disease.
The world has been battling with the COVID-19 pandemic since the end of 2019, which is caused by the highly contagious SARS-CoV-2 with over 25 million confirmed cases all around the world. Although it has been the focus of many studies, this new pandemic is still an enigma in many ways. The severity of the symptoms can vary from mild symptoms with flu-like symptoms and self-limiting disease to severe respiratory symptoms that needs hospitalization and ICU admission and can lead to death. Several factors have been speculated to affect the severity of the COVID-19 infection including genetic factors. In this study, we will investigate the variation in three different SNPs, one for the ACE2 gene which is the binding receptor for the SARS-CoV-2 virus (rs908004, consequence: 3 Prime UTR Variant, Alleles: C>G / C>T), one for the ACE (I/D) gene; which can in term affect the ACE2 receptor and the probability for lung injury ( rs4343, Consequence: Synonymous Variant, Alleles: G>A), and one for the TMPRSS2 gene; which is a transmembrane protease which activates the viral spike by priming it when it is attached to the ACE2 receptor ( rs12329760, consequence: Missense Variant, Alleles: C>T), and conclude if they have any effect in the COVID-19 disease severity and need for hospitalization and admission to the ICU. The aim is:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | COVID-19 carriers who were infected with SARS-CoV-2 and healed without suffering from any respiratory complications or the need for hospitalization | ||
| Group 2 | COVID-19 patients who suffered from serious respiratory complications that needed hospitalization or admission to the ICU |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| ACE I/D gene polymorphism (rs4343) | Genotypic and allele frequencies of the studied SNPS in both study groups | 3 months |
| Angiotensin-converting enzyme 2 (ACE2) gene polymorphism (rs908004) | Genotypic and allele frequencies of the studied SNPS in both study groups | 3 months |
| Type 2 transmembrane serine protease (TMPRSS2) gene polymorphism (rs12329760) | Genotypic and allele frequencies of the studied SNPS in both study groups | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Potential interaction between ACE (I/D), ACE2 and TMPRSS2 gene polymorphisms and the occurrences of severe complications in patients with COVID-19 disease.1 | Genotypic and allele frequencies of all studied SNPS in patients who suffered from serious respiratory complications that needed hospitalization or admission to the ICU | 3 months |
Not provided
Inclusion Criteria:
Ø Positive nasal Swap for COVID-19 Infection. Ø Age of 18 years to 80 years. Ø Written informed consent of the subject to participate in the study.
Exclusion Criteria:
Ø Patients with any prior respiratory problems such Asthma and COPD.
Not provided
Not provided
Egyptian patients who are either : infected with SARS-CoV-2 and healed without suffering from any respiratory complications or the need for hospitalization Or infected with SARS-CoV-2 who suffered from serious respiratory complications that needed hospitalization or admission to the ICU.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Naglaa S Bazan, PhD | Contact | 01005807504 | 002 | naglaabazan@cu.edu.eg |
| Abdelrahman A Abdelgawad, BScPharm | Contact | 01119110322 | 002 | abdelrahman114549@miuegypt.edu.eg |
| Name | Affiliation | Role |
|---|---|---|
| Naglaa S Bazan, PhD | Cairo University | Principal Investigator |
| Khaled Farouk, MD | Cairo University | Principal Investigator |
| Adel RA Abdallah, PhD |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cairo University Hospitals | Recruiting | Cairo | 11562 | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32142651 | Result | Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5. | |
| 32735889 |
Not provided
Not provided
Study protocol
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
A baseline blood sample 3 ml on EDTA tube for genotyping of the studied alleles
| Al-Azhar University in Cairo |
| Study Chair |
| Abdelrahman A Abdelgawad, BScPharm | Misr International University | Principal Investigator |
| Neven MA Sarhan, PhD | Misr International University | Study Director |
| Raed SA Ismail, PhD | Al-Azhar University in Cairo | Study Director |
| Mohamed GL El-Ansary, MD | Cairo University | Study Director |
| Mona Schaalan, PhD | Misr International University | Study Director |
| Zheng H, Cao JJ. Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019. Am J Pathol. 2020 Oct;190(10):2013-2017. doi: 10.1016/j.ajpath.2020.07.009. Epub 2020 Jul 29. |
| 32501810 | Result | Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY). 2020 Jun 5;12(11):10087-10098. doi: 10.18632/aging.103415. Epub 2020 Jun 5. |
| 32664879 | Result | Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, Sharifi N, Erzurum S, Eng C, Cheng F. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020 Jul 15;18(1):216. doi: 10.1186/s12916-020-01673-z. |
| 15381116 | Result | Itoyama S, Keicho N, Quy T, Phi NC, Long HT, Ha LD, Ban VV, Ohashi J, Hijikata M, Matsushita I, Kawana A, Yanai H, Kirikae T, Kuratsuji T, Sasazuki T. ACE1 polymorphism and progression of SARS. Biochem Biophys Res Commun. 2004 Oct 22;323(3):1124-9. doi: 10.1016/j.bbrc.2004.08.208. |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |